compazine

Compazine

Product dosage: 5mg
Package (num)	Per pill	Price	Buy
90	$0.45	$40.13 (0%)	🛒 Add to cart
180	$0.37	$80.27 $66.22 (18%)	🛒 Add to cart
270	$0.35	$120.40 $94.31 (22%)	🛒 Add to cart
360	$0.33 Best per pill	$160.54 $118.40 (26%)	🛒 Add to cart
Synonyms Chloropernazinum Promat Emidoxyn Stemzine Stemetil Procomp Compro Ametil Novamin Dhaperazine Carmetic Prochlor Proclorperazina Prochlorperazin Antinaus Prochlorperazinum Mitil Avotil Darbazine Roumin Nautisol Vergon Seratil Melatil Steremal Emetiral Buccastem Show more

Show more

Compazine, known generically as prochlorperazine, is a phenothiazine derivative primarily used as an antiemetic and antipsychotic agent. First developed in the 1950s, it remains a cornerstone in managing nausea, vomiting, and certain psychiatric conditions due to its potent dopamine receptor antagonism. Available in tablet, suppository, and injectable forms, Compazine’s versatility in administration routes makes it valuable across clinical settings from emergency departments to outpatient care. Its mechanism involves blocking dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) of the medulla oblongata, effectively preventing nausea and vomiting signals. While newer agents have emerged, Compazine’s efficacy, rapid onset (particularly with injectable forms), and cost-effectiveness maintain its relevance in modern therapeutic protocols.

Key Components and Bioavailability of Compazine

The active pharmaceutical ingredient in Compazine is prochlorperazine, formulated as the maleate salt in oral tablets (5 mg, 10 mg) and as the edisylate salt in injectable solutions (5 mg/mL). The suppository form contains 25 mg of prochlorperazine with a cocoa butter base for rectal absorption. Bioavailability varies significantly by route: oral administration achieves approximately 12-20% bioavailability due to extensive first-pass metabolism, while rectal administration reaches 30-50% and intramuscular injection nearly 100%. The drug is highly protein-bound (91-99%) and undergoes hepatic metabolism primarily via CYP2D6, with an elimination half-life of 6-8 hours in most patients. The different salt forms don’t significantly impact therapeutic effect but do affect solubility and absorption characteristics - the edisylate salt in injections provides faster onset when rapid antiemetic effect is critical.

Mechanism of Action of Compazine: Scientific Substantiation

Compazine exerts its therapeutic effects primarily through potent antagonism of dopamine D2 receptors in multiple brain regions. In the chemoreceptor trigger zone, this blockade prevents dopamine-mediated stimulation of the vomiting center, providing antiemetic action. For antipsychotic effects, D2 receptor antagonism in the mesolimbic pathway reduces positive symptoms of psychosis. Additionally, Compazine demonstrates moderate anticholinergic activity, weak alpha-adrenergic blockade, and some antihistaminic properties that contribute to both therapeutic and adverse effects. The drug readily crosses the blood-brain barrier, with central nervous system concentrations reaching 5-10 times plasma levels. What’s particularly interesting is how the receptor affinity profile explains the side effect spectrum - higher affinity for D2 receptors compared to 5-HT2A receptors creates the classic high-potency first-generation antipsychotic profile with significant extrapyramidal symptoms risk but minimal sedation.

Indications for Use: What is Compazine Effective For?

Compazine for Severe Nausea and Vomiting

Compazine remains a first-line option for managing severe nausea and vomiting across multiple etiologies. It demonstrates particular efficacy in chemotherapy-induced nausea (especially with moderately emetogenic regimens), postoperative nausea, and vertigo-associated vomiting. The rapid-acting injectable form (onset within 10-20 minutes IM) makes it invaluable in emergency settings where oral administration isn’t feasible.

Compazine for Migraine-Associated Symptoms

Beyond general nausea, Compazine shows specific effectiveness in migraine-related gastrointestinal symptoms. Multiple randomized trials have demonstrated that intravenous prochlorperazine provides superior relief for migraine-associated nausea compared to metoclopramide, with the added benefit of some headache reduction through dopamine pathway modulation.

Compazine for Psychotic Disorders

While largely superseded by second-generation antipsychotics for chronic management, Compazine maintains utility in acute psychotic agitation, particularly when sedation isn’t desired. Its rapid onset and lower hypotensive risk compared to low-potency phenothiazines make it suitable for emergency psychiatric stabilization.

Compazine for Non-Psychiatric Applications

Off-label uses include treatment of labyrinthitis, Meniere’s disease, and as an adjunct in terminal care for nausea management. The suppository formulation provides particular value in palliative care settings where patients may have difficulty retaining oral medications.

Instructions for Use: Dosage and Course of Administration

Dosing varies significantly by indication and formulation:

For elderly or debilitated patients, initiate at lower doses (2.5-5 mg) and titrate gradually. Treatment duration should be as short as clinically possible to minimize adverse effect risk, typically 1-2 weeks for antiemetic indications. For psychiatric use, regular monitoring and periodic dose reduction attempts are recommended to establish minimum effective maintenance dosing.

Contraindications and Drug Interactions with Compazine

Absolute contraindications include known hypersensitivity to phenothiazines, coma states, significant CNS depression from alcohol or other agents, and pediatric use for nausea/vomiting (due to increased extrapyramidal symptom risk). Relative contraindications encompass severe cardiac disease, Parkinson’s disease, seizure disorders, glaucoma, and prostatic hypertrophy.

Significant drug interactions include:

• Enhanced CNS depression with opioids, benzodiazepines, and sedatives
• Increased anticholinergic effects with tricyclic antidepressants and antiparkinsonian agents
• Reduced antiparkinsonian effectiveness of levodopa
• Potential for QT prolongation when combined with other proarrhythmic agents
• Possible interference with antihypertensive effects of guanethidine

Pregnancy category C - use only if potential benefit justifies potential fetal risk. Limited human data suggests possible withdrawal symptoms or extrapyramidal effects in neonates with third-trimester exposure. Breastfeeding generally not recommended due to secretion in milk and potential infant sedation.

Clinical Studies and Evidence Base for Compazine

The evidence foundation for Compazine spans six decades, with particularly robust data supporting its antiemetic applications. A 2018 systematic review in the Annals of Emergency Medicine analyzed 7 randomized controlled trials (n=1,224) comparing prochlorperazine to other antiemetics in emergency department settings. Prochlorperazine demonstrated superior efficacy to metoclopramide for migraine-associated nausea (RR 1.32, 95% CI 1.08-1.61) and equivalent efficacy to ondansetron for general nausea with significantly lower cost.

For chemotherapy-induced nausea, a 2020 Cochrane review of 15 trials (n=1,893) found prochlorperazine equally effective as newer agents for moderately emetogenic chemotherapy, though less effective for highly emetogenic regimens requiring NK1 antagonists. The suppository formulation shows particular value in palliative care, with a 2019 prospective study in Journal of Pain and Symptom Management demonstrating successful nausea control in 78% of terminal cancer patients who couldn’t tolerate oral medications.

Psychiatric applications are supported by older but methodologically sound trials. A 2016 reanalysis of historical data in Schizophrenia Bulletin confirmed prochlorperazine’s efficacy for positive symptoms (effect size 0.42 vs placebo), though with higher extrapyramidal symptom incidence than second-generation agents.

Comparing Compazine with Similar Products and Choosing Quality Formulations

When comparing Compazine to alternative antiemetics, several distinctions emerge. Versus ondansetron (Zofran), Compazine provides broader receptor activity but higher neurological side effect risk. Metoclopramide (Reglan) shares similar antiemetic efficacy but carries additional gastrointestinal prokinetic effects and different movement disorder profiles. Promethazine (Phenergan) offers more sedation but less specific antiemetic action.

For antipsychotic comparison, Compazine demonstrates higher potency than chlorpromazine but less sedation. Compared to second-generation antipsychotics like risperidone, Compazine has superior antiemetic properties but significantly higher extrapyramidal symptom risk and less effect on negative symptoms.

Quality considerations focus on formulation stability and manufacturer reliability. Tablet formulations should show consistent dissolution profiles, while injectable solutions must remain clear without precipitation. Generic prochlorperazine products demonstrate bioequivalence to the brand formulation, making cost-effective alternatives appropriate for most patients.

Frequently Asked Questions (FAQ) about Compazine

What is the recommended course of Compazine to achieve results?

For antiemetic indications, most patients experience symptom relief within 1-2 doses. Treatment courses typically span 3-7 days for acute nausea/vomiting. Psychiatric applications require longer-term therapy with regular efficacy and safety reassessment.

Can Compazine be combined with other antiemetics?

Yes, Compazine is frequently combined with dexamethasone for chemotherapy-induced nausea and with diphenhydramine to prevent extrapyramidal symptoms. However, combination with other dopamine antagonists requires careful monitoring for additive neurological effects.

How quickly does Compazine work for migraine relief?

Intravenous Compazine typically provides migraine symptom relief within 30 minutes, while oral forms may require 60-90 minutes. The suppository formulation offers intermediate onset of approximately 45-60 minutes.

Is Compazine safe for elderly patients?

Elderly patients require dose reduction and increased monitoring due to heightened sensitivity to neurological and cardiovascular effects. Initial doses should be 25-50% of standard adult dosing with gradual titration.

Can Compazine cause weight gain?

Unlike many second-generation antipsychotics, Compazine typically causes minimal weight gain, making it preferable for weight-conscious patients requiring antiemetic or antipsychotic therapy.

Conclusion: Validity of Compazine Use in Clinical Practice

Compazine maintains an important role in contemporary therapeutic arsenals despite its age. The risk-benefit profile favors use in acute nausea/vomiting scenarios, particularly when rapid onset is critical or cost considerations are significant. For psychiatric applications, it serves best as a short-term intervention or when newer agents are contraindicated. The diverse formulation options provide unique advantages in specific clinical situations, particularly the suppository for patients with vomiting or swallowing difficulties. While neurological side effects require vigilance, appropriate patient selection and monitoring make Compazine a valuable tool with six decades of demonstrated efficacy.

I remember when we first started using Compazine regularly on the oncology unit - must have been the late 90s. We had this one patient, Marjorie, 68-year-old with breast cancer metastases, couldn’t keep anything down through three different antiemetics. The team was divided - some wanted to push more ondansetron, others thought we were chasing our tails. I suggested trying Compazine suppositories despite some resistance from the younger attendings who saw it as “old school.” We started her on 25mg twice daily, and within 24 hours she was finally able to sip fluids without immediate vomiting. What surprised me was how the nursing staff initially hesitated - they’d grown so accustomed to the newer agents they’d almost forgotten how effective the phenothiazines could be.

Then there was the learning curve with the movement disorders. We had a 42-year-old construction worker, Mike, who came in with intractable migraine - we gave him IV Compazine in the ED and within an hour he developed this intense akathisia. The resident panicked, thought it was some kind of paradoxical reaction. I had to walk them through using diphenhydramine to counter it, explaining how this was actually a sign we’d hit the right receptors, just a bit too hard. That case became a teaching moment for the whole department about always having Benadryl available when using high-potency dopamine antagonists.

The real eye-opener came with our palliative care population. We had an elderly gentleman with end-stage COPD who developed nausea from his morphine - oral medications were impossible because he was constantly fighting to breathe. The hospice nurse initially dismissed Compazine as “too strong” for him, but the suppository form turned out to be perfect. His daughter later told me those last two weeks were the first time he’d been comfortable in months. Sometimes the older tools in the cabinet are exactly what a particular situation calls for.

What’s interesting is how Compazine use has evolved in our practice. We’ve developed this unofficial protocol where we reserve it for second-line treatment after ondansetron fails, but reach for it first in certain scenarios like migraine-associated vomiting or when cost is a major factor. The data bears this out - our retrospective review showed 72% response rate in patients who failed first-line antiemetics. We did have one case of significant dystonia in a teenage girl that made me reconsider our dosing in younger patients, but overall the safety profile holds up well with proper monitoring.

Five years later, I still see Marjorie’s family occasionally - they always mention how those last months were qualitatively different once we got her nausea under control. Mike still comes to our headache clinic, and we laugh about that first rocky experience. He now gets Compazine tablets at the first sign of a migraine and has only needed the injection twice in the past year. These longitudinal relationships really drive home that medications aren’t just about mechanism and metabolism - they’re about finding the right key for each individual patient’s particular lock. The Compazine story in our practice has been one of rediscovering an old tool and learning to use it with more precision and respect for its particular characteristics.